Revance Therapeutics (RVNC) News Today $3.68 +0.41 (+12.54%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 20 at 4:00 PM | globenewswire.comRVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. ...January 20 at 11:42 AM | gurufocus.comRVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 20 at 10:57 AM | prnewswire.comHold Rating Maintained Amidst Revised Acquisition Proposal for Revance TherapeuticsJanuary 20 at 10:41 AM | markets.businessinsider.comInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 ...January 20 at 6:08 AM | gurufocus.comInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCJanuary 20 at 5:45 AM | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 19 at 4:00 PM | businesswire.comNeedham & Company LLC Reiterates Hold Rating for Revance Therapeutics (NASDAQ:RVNC)January 19 at 3:02 AM | americanbankingnews.comHold Rating Recommended Amid Competitive Bidding War for Revance TherapeuticsJanuary 18 at 4:20 AM | markets.businessinsider.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 17 at 4:00 PM | prnewswire.comRevance Therapeutics' (RVNC) "Hold" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating on shares of Revance Therapeutics in a research note on Friday.January 17 at 12:59 PM | marketbeat.comRevance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 17 at 12:00 PM | prnewswire.comLevi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNCJanuary 17 at 5:45 AM | prnewswire.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Down 14.6% in DecemberRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 8,340,000 shares, a drop of 14.6% from the December 15th total of 9,770,000 shares. Based on an average daily volume of 2,720,000 shares, the short-interest ratio is currently 3.1 days.January 16, 2025 | marketbeat.comMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCJanuary 16, 2025 | globenewswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCJanuary 16, 2025 | prnewswire.comShareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCJanuary 15, 2025 | globenewswire.comRevance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 15, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNCJanuary 14, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 14, 2025 | globenewswire.comFNY Investment Advisers LLC Raises Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)FNY Investment Advisers LLC raised its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 160.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 477,823 shares of the biopharmaceutical company's stocJanuary 14, 2025 | marketbeat.comCrown Laboratories Extends Tender Offer To Acquire Revance Therapeutics, Inc.January 13, 2025 | markets.businessinsider.comCrown Laboratories, Inc.: Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.January 13, 2025 | finanznachrichten.deCrown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.January 13, 2025 | prnewswire.comShareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreJanuary 13, 2025 | prnewswire.comRevance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.comStockNews.com initiated coverage on Revance Therapeutics in a research report on Monday. They set a "hold" rating for the company.January 13, 2025 | marketbeat.comDeadline Alert: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJanuary 10, 2025 | tmcnet.comDeadline Alert: Revance Therapeutics, Inc. ...January 10, 2025 | gurufocus.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 10, 2025 | businesswire.comKirby McInerney LLP Reminds Revance Therapeutics, Inc. ...January 10, 2025 | gurufocus.comKirby McInerney LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Class Action Filing and Encourages Investors to Contact the FirmJanuary 10, 2025 | globenewswire.comRevance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNCJanuary 10, 2025 | prnewswire.comRVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 10, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 9, 2025 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCJanuary 9, 2025 | prnewswire.comCohen Milstein Urges Shareholders Who Lost Significant Money In Revance Therapeutics, Inc. To Contact FirmJanuary 8, 2025 | stockhouse.comRevance stock rises after entering talks with Teoxane on potential higher takeover offerJanuary 8, 2025 | au.investing.comRevance to Hold Talks With Teoxane on Takeover ProposalJanuary 8, 2025 | marketwatch.comRevance gains as it plans to enter talks with Teoxane on likely superior bidJanuary 8, 2025 | msn.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join – Contact Levi & KorsinskyJanuary 8, 2025 | globenewswire.comREVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the FirmJanuary 7, 2025 | globenewswire.comRVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 7, 2025 | businesswire.comStockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action LawsuitJanuary 7, 2025 | prnewswire.comRVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 7, 2025 | globenewswire.comLaw Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class ActionJanuary 7, 2025 | businesswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. (RVNC)January 7, 2025 | globenewswire.comHold Rating on Revance Therapeutics Amid Acquisition Bid UncertaintyJanuary 7, 2025 | markets.businessinsider.comRVNC ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. InvestorsJanuary 7, 2025 | markets.businessinsider.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class ActionJanuary 6, 2025 | businesswire.comLaw Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class ActionJanuary 6, 2025 | businesswire.com Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Media Mentions By Week RVNC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVNC News Sentiment▼0.060.44▲Average Medical News Sentiment RVNC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVNC Articles This Week▼225▲RVNC Articles Average Week Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News Today EVO News Today IMCR News Today DYN News Today TVTX News Today VIR News Today SDGR News Today NRIX News Today XNCR News Today KNSA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVNC) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVNC Stock Alerts